Valuation: Genovis AB

Market Cap 1.32B 138M 120M 112M 103M 194M 13.22B 197M 518M 6.58B 520M 509M 22.07B P/E 2026 *
55.9x
P/E 2027 * 35.2x
Enterprise Value 1.21B 126M 110M 102M 93.91M 177M 12.07B 180M 473M 6.01B 475M 464M 20.15B EV / Sales 2026 *
8.22x
EV / Sales 2027 * 6.36x
Free-Float
92.6%
Yield 2026 *
-
Yield 2027 * -
1 day-0.71%
1 week-2.34%
1 month-4.49%
3 months+0.93%
6 months-9.56%
Current year-7.86%
1 week 18.96
Extreme 18.96
20.85
1 month 18.22
Extreme 18.22
21.2
Current year 15.64
Extreme 15.64
23.65
1 year 15.64
Extreme 15.64
28.15
3 years 15.64
Extreme 15.64
57.6
5 years 15.64
Extreme 15.64
90
10 years 1.66
Extreme 1.66
90
Manager TitleAgeSince
Chief Executive Officer 55 05/05/2015
Director of Finance/CFO 55 01/01/2022
Chief Tech/Sci/R&D Officer 42 01/01/2017
Director TitleAgeSince
Director/Board Member 77 01/01/2014
Director/Board Member 65 01/01/2019
Chairman 74 05/05/2020
Date Insider Type Main position Quantity % Market Cap.
2/24/26 A Buy

Chief Financial Officer

3,137 0.0047%
2/24/26 A Buy

Chief Financial Officer

2,470 0.0037%
2/20/26 A Buy

Chief Financial Officer

5,813 0.0088%
Change 5-day change 1-year change 3-year change Capi.($)
-0.71%-2.34%-26.53%-58.99% 138M
+6.33%+9.95%+291.09%+326.35% 21.74B
-3.83%-1.14%-44.32%-27.66% 9.38B
-1.35%-4.94%+41.19%+19.19% 6.49B
-4.37%+2.16%+261.39%-24.06% 6B
-1.81%-0.93%-11.76%-13.45% 5.57B
-2.61%+0.97%-44.12% - 4.43B
+4.21%+7.67%-16.64%-27.25% 4.38B
+9.99%+1.30%+74.78%+93.55% 4.25B
-1.02%+5.24%-17.29%-39.41% 2.8B
Average +0.48%+1.26%+50.78%+27.58% 6.52B
Weighted average by Cap. +1.58%+3.41%+117.84%+113.59%

Financials

2026 *2027 *
Net sales 147M 15.38M 13.37M 12.45M 11.43M 21.58M 1.47B 21.92M 57.59M 731M 57.78M 56.51M 2.45B 183M 19.18M 16.67M 15.52M 14.25M 26.9M 1.83B 27.32M 71.78M 911M 72.02M 70.44M 3.06B
Net income 21.63M 2.27M 1.97M 1.84M 1.69M 3.18M 217M 3.23M 8.49M 108M 8.52M 8.33M 361M 38.9M 4.08M 3.55M 3.3M 3.03M 5.72M 389M 5.81M 15.27M 194M 15.32M 14.98M 650M
Net Debt -115M -12.07M -10.5M -9.77M -8.97M -16.94M -1.15B -17.2M -45.19M -574M -45.34M -44.35M -1.92B -158M -16.62M -14.45M -13.45M -12.35M -23.31M -1.59B -23.67M -62.21M -790M -62.41M -61.04M -2.65B
Logo Genovis AB
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Employees
42
Date Price Change Volume
31/07/26 SEK 19.58 -0.71% 34,470
30/07/26 SEK 19.72 +0.61% 54,833
29/07/26 SEK 19.60 -3.21% 33,981
28/07/26 SEK 20.25 +1.00% 49,433
27/07/26 SEK 20.05 -.--% 19,992
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
19.58SEK
Average target price
33.00SEK
Spread / Average Target
+68.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENO Stock